Skip to content
Home/Companies/Biotech/Kano Therapeutics
Kano Therapeutics

Kano Therapeutics

Biotech·United States·Active·2yr hold
Entry
2024
Hold
2yr
Status
Active

Who owns Kano Therapeutics?

Kano Therapeutics is an American Biotech company, currently owned by Vsquared Ventures since 2024.

Hand-verified · updated 2026-07-07

Open JSON · CC-BY
Vsquared Ventures
Investor
Vsquared Ventures
Vsquared Ventures II · 2024 · VC

Key facts

HQUnited States
SectorBiotech
StatusActive
Websitekanotherapeutics.com

More from Vsquared Ventures II

Other portfolio companies in the same fund.

Arlequin AI
Active
SoftwareFrance· 2025
Atrandi Biosciences
Atrandi Biosciences
Active
BiotechLithuania· 2025
Belfort
Belfort
Active
Deep TechBelgium· 2025
Hedera Dx
Hedera Dx
Active
MedTechSwitzerland· 2025
Pulsetrain
Active
MobilityGermany· 2025
Cylib
Cylib
Active
ClimateTechGermany· 2024

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS

Questions

Who owns Kano Therapeutics?

Kano Therapeutics is currently owned by Vsquared Ventures, through Vsquared Ventures II, since 2024.

When did Vsquared Ventures acquire Kano Therapeutics?

Vsquared Ventures acquired Kano Therapeutics in 2024.

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue